Get unlimited access to Bruins cup coverage - Just 99¢

The Boston Globe

Business

Boston.com

After coup, Verastem navigates choppy waters

By Robert Weisman

 |  Globe Staff  

  May 23, 2012

Two-year-old Verastem Inc., which raised $55 million in an initial public offering in late January, was one of the first biotechnology start-ups in years to take its shares public before its drugs entered clinical trials. Four months later, as executives Tuesday rang the opening bell on the Nasdaq exchange remotely from their research lab here, the company’s shares have been buffeted by the volatile stock market. They closed the day at $9.58, down 4.2 percent from Monday’s close and 21.7 percent from their peak in March.

Stay with the story. Get full access to BostonGlobe.com for just 99¢

Unlimited access to BostonGlobe.com for only 99¢ for the first 4 weeks. You can cancel at any time.

  • The FULL story all day: Enjoy all of the high-quality, in-depth journalism in the print edition of the Boston Globe — plus breaking news that's updated 24/7.
  • A truly reader-friendly format: It's online news that looks and reads just like the newspaper — uncluttered, uninterrupted.
  • Breakthrough technology: The responsive design automatically adapts content so it always reads perfectly on the digital device of your choice.
Get started today

Free access for home delivery subscribers.

Just need to link your home delivery account; one easy step.

Link my home delivery account

BostonGlobe.comSubscriber Log In

Contact us for help

  • Phone

    888-MY-GLOBE

    Monday-Friday 6:00 a.m.- 5:00 p.m.

    Saturday, Sunday and Holidays 7:30 a.m.- 12:00 noon

  • Chat

    Start a chat

    Monday-Sunday 8:00 a.m.- 5:00 p.m.

  • E-mail

    support@bostonglobe.com